Business
Biora Therapeutics wins new patent covering Biojet liquid jet delivery technology
- Biora Therapeutics (NASDAQ:BIOR) Monday announced the issuance of a new patent related to the company’s BioJet platform for oral, systemic delivery of biotherapeutics.
- The issued claims cover key jet parameters for liquid jet delivery of a drug to the gastrointestinal (GI) tract, including the stomach or small intestine.
- “This latest patent further secures Biora’s broad and comprehensive ownership of liquid jet delivery to the GI tract. The BioJet platform’s liquid jet injection technology, with systemic bioavailability and consistency shown to be comparable to traditional subcutaneous injection, is outperforming our performance targets in preclinical testing,” said Adi Mohanty, Biora CEO.
- The BioJet platform’s potential to deliver large molecules, including GLP-1 agonists, monoclonal antibodies, antisense oligonucleotides, and many others, and to achieve liver-targeted delivery through the hepatic portal, could transform oral delivery of therapeutics,” Mohanty added.
- These patents are part of Biora’s larger corporate portfolio consisting of 73 patent families, including approximately 190 issued patents and 136 pending applications in major jurisdictions around the world, including the US, Europe, Canada, China, Japan, South Korea, Israel, Australia and Mexico.
- Source: Press Release
More on Biora Therapeutics
Source link
